| Bioactivity | (rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus[1][2][3]. |
| CAS | 2328064-33-9 |
| Formula | C18H17D3N6O4S |
| Molar Mass | 419.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111. [2]. Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66(7): 4378-4416. [3]. Andrew Nicholas Billin, et al. Il-31 modulators for treating fxr-induced pruritis. WO2022266444A1. 2022-06-17 |
(rac)-Lomedeucitinib
CAS: 2328064-33-9 F: C18H17D3N6O4S W: 419.47
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine pro
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.